3B Blackbio Diagnostics Ltd Stock Price Today (NSE: 3BBLACKBIO)
Fundamental Score
3B Blackbio Diagnostics Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
3B Blackbio Diagnostics Ltd share price today is ₹1126.00, down 4.20% on NSE/BSE as of 30 March 2026. 3B Blackbio Diagnostics Ltd (3BBLACKBIO) is a Small-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹1.08K (Cr). The 52-week high for 3BBLACKBIO share price is ₹2019.90 and the 52-week low is ₹1151.00. At a P/E ratio of 22.01x, 3BBLACKBIO is currently trading below its industry average P/E of 39.28x. The company has a Return on Equity (ROE) of 19.40% and a debt-to-equity ratio of 0.00.
3B Blackbio Diagnostics Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
3B Blackbio Diagnostics Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Financial Analysis of 3B Blackbio Diagnostics Share Price
One evolving trend in the Healthcare Service Provider industry is the increased demand for specialized diagnostics, creating niche opportunities for companies with targeted solutions. This analysis provides an observational overview of the financial standing of 3B Blackbio Diagnostics Ltd, focusing specifically on the determinants of the "3B Blackbio Diagnostics share price." The current share price is ₹1627.550049, with a Price-to-Earnings (PE) ratio of 22.01. This ratio suggests how much investors are willing to pay for each rupee of earnings, offering a snapshot of market sentiment.
A crucial metric indicating the company's efficiency is its Return on Capital Employed (ROCE) of 25.75%. This figure represents the profitability generated from the capital invested in the business. A high ROCE, such as 3B Blackbio Diagnostics' 25.75%, indicates effective capital allocation and can contribute significantly to the company's economic moat. This profitability allows for reinvestment, innovation, and strategic acquisitions, bolstering its competitive edge over time.
When compared to its peers, such as
Suraksha Diagnostic Ltd, understanding differences in management quality becomes critical. The ability of the management team to effectively navigate the complex healthcare landscape, maintain operational efficiency, and adapt to market changes is paramount. The differences in management quality is based on observable factors, such as business decisions and operational efficiencies as reported in regulatory disclosures. Comparing 3B Blackbio Diagnostics Ltd's management approach with those of companies like Aspira Pathlab & Diagnostics Limited and Gian Life Care Ltd can offer insights into its long-term sustainability.This financial analysis is an excerpt from a comprehensive 80-parameter fundamental audit performed under the supervision of Sweta Mishra, a financial specialist. The intent is to provide an objective assessment of available data points, not to offer any investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
3B Blackbio Diagnostics Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of 3BBLACKBIO across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (19.40%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (25.75%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (55.44%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 22.01 vs Industry: 39.28)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (16.30%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (27.29% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (40.23% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (44.03% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (599.27x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹218.07 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Limited Institutional Interest (FII+DII: 4.46%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
3B Blackbio Diagnostics Ltd Financial Statements
Comprehensive financial data for 3B Blackbio Diagnostics Ltd including income statement, balance sheet and cash flow
About 3BBLACKBIO (3B Blackbio Diagnostics Ltd)
3B Blackbio Diagnostics Ltd is a pioneering force in the healthcare sector, dedicated to revolutionizing disease detection and management through innovative molecular diagnostic so...lutions. The company is deeply invested in designing, developing, and manufacturing cutting-edge diagnostic tools that span a wide range of critical medical fields. From the intricate complexities of infectious diseases and oncology to the nuanced landscape of human genetics and the ever-growing threat of antimicrobial resistance, 3B Blackbio is committed to providing healthcare professionals with the power to make informed decisions, ultimately improving patient outcomes. At the heart of 3B Blackbio's mission lies a comprehensive portfolio of molecular diagnostic kits, each meticulously crafted to deliver accurate and reliable results. These kits utilize advanced technologies such as qPCR-based assays, rapid lateral flow tests, and Next Generation Sequencing (NGS), ensuring a versatile approach to diagnostics. Marketed under the TRUPCR, TRUNGS, and TRURAPID brands, these solutions empower diagnostic laboratories to perform comprehensive testing on patient samples, enabling faster and more precise diagnoses. The company's commitment to innovation and quality ensures that healthcare providers have access to the most advanced tools available. 3B Blackbio Diagnostics Ltd stands as a vital partner in the fight against disease, striving to empower clinicians with the knowledge they need to provide the best possible care. By continuously pushing the boundaries of molecular diagnostics, 3B Blackbio is not only transforming the way diseases are detected and managed, but also contributing to a healthier future for all. Their dedication to innovation, accuracy, and accessibility makes them a key player in the evolving landscape of healthcare.
Company Details
Key Leadership
Corporate Events
Latest News
3BBLACKBIO Share Price: Frequently Asked Questions
What is the current share price of 3B Blackbio Diagnostics Ltd (3BBLACKBIO)?
As of 30 Mar 2026, 12:06 pm IST, 3B Blackbio Diagnostics Ltd share price is ₹1126.00. The 3BBLACKBIO stock has a market capitalisation of ₹1.08K (Cr) on NSE/BSE.
Is 3BBLACKBIO share price Overvalued or Undervalued?
3BBLACKBIO share price is currently trading at a P/E ratio of 22.01x, compared to the industry average of 39.28x. Based on this relative valuation, the 3B Blackbio Diagnostics Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of 3BBLACKBIO share price?
The 52-week high of 3BBLACKBIO share price is ₹2019.90 and the 52-week low is ₹1151.00. These values are updated daily from NSE/BSE price data.
What factors affect the 3B Blackbio Diagnostics Ltd share price?
Key factors influencing 3BBLACKBIO share price include quarterly earnings growth (Sales Growth: 16.30%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is 3B Blackbio Diagnostics Ltd a good stock for long-term investment?
3B Blackbio Diagnostics Ltd shows a 5-year Profit Growth of 44.03% and an ROE of 19.40%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in 3BBLACKBIO shares.
How does 3B Blackbio Diagnostics Ltd compare with its industry peers?
3B Blackbio Diagnostics Ltd competes with major peers in the Healthcare Service Provider. Investors should compare 3BBLACKBIO share price P/E of 22.01x and ROE of 19.40% against the industry averages to determine competitive standing.
What is the P/E ratio of 3BBLACKBIO and what does it mean?
3BBLACKBIO share price has a P/E ratio of 22.01x compared to the industry average of 39.28x. Investors pay ₹22 for every ₹1 of annual earnings.
How is 3BBLACKBIO performing according to Bull Run's analysis?
3BBLACKBIO has a Bull Run fundamental score of 66.1/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does 3BBLACKBIO belong to?
3BBLACKBIO operates in the Healthcare Service Provider industry. This classification helps understand the competitive landscape and sector-specific trends affecting 3B Blackbio Diagnostics Ltd share price.
What is Return on Equity (ROE) and why is it important for 3BBLACKBIO?
3BBLACKBIO has an ROE of 19.40%, which indicates excellent management efficiency. ROE measures how efficiently 3B Blackbio Diagnostics Ltd generates profits from shareholders capital.
How is 3BBLACKBIO debt-to-equity ratio and what does it indicate?
3BBLACKBIO has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is 3BBLACKBIO dividend yield and is it a good dividend stock?
3BBLACKBIO offers a dividend yield of 0.32%, meaning you receive ₹0.32 annual dividend for every ₹100 invested in 3B Blackbio Diagnostics Ltd shares.
How has 3BBLACKBIO share price grown over the past 5 years?
3BBLACKBIO has achieved 5-year growth rates of: Sales Growth 27.29%, Profit Growth 44.03%, and EPS Growth 40.23%.
What is the promoter holding in 3BBLACKBIO and why does it matter?
Promoters hold 41.28% of 3BBLACKBIO shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in 3B Blackbio Diagnostics Ltd.
What is 3BBLACKBIO market capitalisation category?
3BBLACKBIO has a market capitalisation of ₹1081 crores, placing it in the Small-cap category.
How volatile is 3BBLACKBIO stock?
3BBLACKBIO has a beta of N/A. A beta > 1 suggests the 3B Blackbio Diagnostics Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is 3BBLACKBIO operating profit margin trend?
3BBLACKBIO has a 5-year average Operating Profit Margin (OPM) of 55.44%, indicating the company's operational efficiency.
How is 3BBLACKBIO quarterly performance?
Recent quarterly performance shows 3B Blackbio Diagnostics Ltd YoY Sales Growth of 16.30% and YoY Profit Growth of 0.41%.
What is the institutional holding pattern in 3BBLACKBIO?
3BBLACKBIO has FII holding of 2.64% and DII holding of 1.82%. Significant institutional holding often suggests professional confidence in the 3B Blackbio Diagnostics Ltd stock.